Breaking News

BioFocus, Aviva Ink Lab Pact

September 3, 2013

To build 60,000-sq.-ft. lab at Chesterford Research Park

BioFocus has signed a pre-let agreement with Aviva Investors for the new Robinson Building, a 60,000-sq.-ft. lab facility at Chesterford Research Park near Cambridge, UK. BioFocus will combine the majority of its drug discovery groups in the new complex to support integrated projects. The Robinson Building has outline planning permission and construction is expected to begin immediately.
Chris Newton, managing director of BioFocus, said, “BioFocus has been expanding its research activities at Chesterford Park, bringing our expertise in different areas such as structural biology, complex cell assays, and medicinal chemistry closer together.  Moving many of these teams into a single, modern and efficient building is an important step forward for the company and will bring added synergies to both our business model and to our scientists.”
Julian Cobourne, asset manager for Aviva Investors, said, “Chesterford Research Park has provided significant support to BioFocus in meeting its property needs over the years and it has been great to work with them to design a much more efficient laboratory building to meet their future requirements.”
  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics